Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 147 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Inactive Substance Clear all
Completed Phase 3 Interventional

Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) in Children

NCT00031395
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
clonidine, methylphenidate, placebo
Drug · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
7 Years to 12 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
4
States / cities
Buffalo, New York • Rochester, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 21, 2009 · Synced Oct 19, 2026, 7:20 AM EDT
Terminated Phase 2 Interventional Results available

Corticosteroids With Placebo Versus Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)

NCT01074437
View directory record Official record
Conditions
Hemangioma
Interventions
Prednisolone (Corticosteroid), Propranolol, Placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 9 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Oct 19, 2026, 7:20 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

NCT06546670
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
ITU512, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 55 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
9
States / cities
Birmingham, Alabama • Miami, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Phase 3 Interventional

Omega-3 Fatty Acids for Treating Adults With Major Depression

NCT00517036
View directory record Official record
Conditions
Depression
Interventions
EPA omega-3 fatty acid, DHA omega-3 fatty acid, Placebo comparator
Dietary Supplement
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Phase 3 Interventional Results available

Hyper- and Hypokalemic Periodic Paralysis Study

NCT00494507
View directory record Official record
Conditions
Hyperkalemic Periodic Paralysis, Hypokalemic Periodic Paralysis
Interventions
Dichlorphenamide (double-blind), Placebo (double-blind), Dichlorphenamide (open-label)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Kansas City, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 19, 2026, 7:20 AM EDT
Terminated Phase 3 Interventional Results available

NET-PD LS-1 Creatine in Parkinson's Disease

NCT00449865
View directory record Official record
Conditions
Parkinson's Disease
Interventions
creatine, placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
1,741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Phase 4 Interventional

Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement

NCT00752869
View directory record Official record
Conditions
Hypogonadism
Interventions
dutasteride, placebo
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine)

NCT05890586
View directory record Official record
Conditions
Covid19
Interventions
Fluvoxamine, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
91
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Phase 4 Interventional Results available

Trial of Levomilnacipran in Geriatric Depression

NCT02466958
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
levomilnacipran, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Unacylated Ghrelin to Improve Functioning in PAD

NCT04377126
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Ghrelin, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
55 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Phase 4 Interventional Results available

Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder

NCT00955955
View directory record Official record
Conditions
Depression
Interventions
6(S)-5-MTHF(Deplin), Placebo
Other
Lead sponsor
George I. Papakostas
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
San Diego, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Phase 3 Interventional Results available

Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization

NCT01973998
View directory record Official record
Conditions
COPD
Interventions
Roflumilast, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
40 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study

NCT02081404
View directory record Official record
Conditions
Non-erosive Reflux Disease
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Phase 3 Interventional Results available

Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx

NCT00211887
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Interferon beta 1-a, glatiramer acetate, placebo
Drug · Other
Lead sponsor
Fred Lublin
Other
Eligibility
18 Years to 60 Years
Enrollment
1,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Phase 2 Interventional

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

NCT06436183
View directory record Official record
Conditions
Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
Interventions
Camoteskimab, Placebo
Drug
Lead sponsor
Apollo Therapeutics Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
30
States / cities
Phoenix, Arizona • Encinitas, California • Fountain Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety of Rifaximin With NAC in IBS-D

NCT04557215
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Rifaximin, N-acetylcysteine, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Citicoline for Bipolar 1 Disorder and Cocaine Dependence

NCT00619723
View directory record Official record
Conditions
Bipolar Disorder, Cocaine Dependence
Interventions
Citicoline, Placebo, Cognitive Behavioral Therapy (CBT)
Drug · Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 19, 2026, 7:20 AM EDT
Terminated Phase 2 Interventional Results available

KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis

NCT03919799
View directory record Official record
Conditions
System; Sclerosis, Diffuse Cutaneous Systemic Sclerosis
Interventions
Belumosudil (KD025), Placebo
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 100 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600)

NCT05894538
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
93
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Not applicable Interventional Results available

Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia

NCT00793780
View directory record Official record
Conditions
Obesity, Schizophrenia, Schizoaffective Disorder
Interventions
Naltrexone 25mg, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Not applicable Interventional

Exercise is Medicine at Emory Seavey Internal Medicine Clinic

NCT03416634
View directory record Official record
Conditions
Physical Activity
Interventions
App, Wearable Device, Automated Motivational Message, Personalized Motivational Message
Behavioral
Lead sponsor
Emory University
Other
Eligibility
20 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Not applicable Interventional Results available

Pregabalin in CIPN

NCT02394951
View directory record Official record
Conditions
Neuropathy, Pain
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 19, 2026, 7:20 AM EDT
Terminated Phase 3 Interventional Results available

Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease

NCT01751802
View directory record Official record
Conditions
Lesch-Nyhan Disease, Self-injurious Behavior
Interventions
Ecopipam, Placebo
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
6 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 19, 2026, 7:20 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)

NCT05736861
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
87
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 19, 2026, 7:20 AM EDT